TrialClinical and translational science2021

First-in-human study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of ALPN-101, a dual CD28/ICOS antagonist, in healthy adult subjects.

Jing Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.